** Shares of Chinese immunology diseases therapeutics developer Hbm Holdings Ltd 2142.HK rise 4.8% to HK$6.27, their highest since January 2022, and on course for second session of gains
** Hbm says co, as a licensor in a license agreement for product HBM9378/SKB378, has received an upfront payment from licensee Windward Bio AG, which will bolster co's cash reserves
** It gives no further details
** Hong Kong's healthcare index .HSCIH climbs 1.1%, Hang Seng Index .HSI rises 2.5%
** Stock up 221.5% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。